The CARE-HF trial evaluates the effects of Cardiac Resynchronization (CR) therapy on the mortality and morbidity of patients with heart failure due to left ventricular systolic dysfunction already receiving diuretics and optimal medical therapy.
813 patients enrolled 82 centers in 12 countries (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, and UK)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
813
All cause mortality or unplanned cardiovascular hospitalization.
All cause mortality
All cause mortality or unplanned hospitalization for or with worsening Heart Failure
Days alive and not in hospital for unplanned cardiovascular cause
Days alive and not in hospital for any reason
NYHA class at 90 days
QOL at 90 days
End of study status
MECHANISTIC OUTCOME:Echocardiographic parameters, Neurohormonal parameters, Therapy delivery assessment
HEALTH ECONOMIC OUTCOME:Cost effectiveness of cardiac resynchronization will be assessed.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.